Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Houston, TX
Treatments:Biologic therapyHospital:The University of Texas M. D. Anderson Cancer Center
Drugs:Journal:Link
Date:Feb 2009

Description:

Patients:
This phase II study involved 40 advanced hepatocellular carcinoma patients with a median age of 64 years; 77.5% were male.

Treatment:
Patients were treated with a combination of two biologic therapy agents, bevacizumab and erlotinib (a small molecular inhibitor of epidermal growth factor receptor tyrosine kinase, which is involved in cell growth and survival).

Toxicities:
There was one treatment-related death due to gastrointestinal bleeding. Grade 3 acne, delayed wound healing, fatigue, and diarrhea were also reported.

Results:
The median overall survival was 15.6 months.

Support:
Some of the authors have received funding from Genentech, makers of bevacizumab and erlotinib.

Correspondence: Dr. Melanie B. Thomas; email: [email protected]



Back